gilteritinib + LoDAC (Low Dose Cytarabine) + Azacitidine + MEC (Mitoxantrone, Etoposide, Cytarabine) + FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Leukemia, Acute Myeloid (AML)
Conditions
Leukemia, Acute Myeloid (AML)
Trial Timeline
Oct 20, 2015 → Feb 25, 2025
NCT ID
NCT02421939About gilteritinib + LoDAC (Low Dose Cytarabine) + Azacitidine + MEC (Mitoxantrone, Etoposide, Cytarabine) + FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)
gilteritinib + LoDAC (Low Dose Cytarabine) + Azacitidine + MEC (Mitoxantrone, Etoposide, Cytarabine) + FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin) is a phase 3 stage product being developed by Astellas Pharma for Leukemia, Acute Myeloid (AML). The current trial status is completed. This product is registered under clinical trial identifier NCT02421939. Target conditions include Leukemia, Acute Myeloid (AML).
What happened to similar drugs?
20 of 20 similar drugs in Leukemia, Acute Myeloid (AML) were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02421939 | Phase 3 | Completed |
Competing Products
20 competing products in Leukemia, Acute Myeloid (AML)